Sunday, November 1, 2026

Marathon Stock Soars 12% In Bullish Momentum On Monday

ViaNews Editorial Team

October 23, 2023

Marathon Stock Soars 12% In Bullish Momentum On Monday

(VIANEWS) - Marathon Shares Propel 12.75% Gain on NASDAQ as Stock Market Rebounds Marathon (NASDAQ: MARA) shares surged 12.75% to EUR8.75 at 13:23 EST Monday afternoon, continuing the upward trend from previous sessions and outperforming broader markets which rose only 1.11% - marking an unusual change after four sessions of losses for Marathon. Marathon's closing price today was EUR7.76, marking an enormous 60.97% decline from its 52-week high of EUR19.88. However, its impressive performance today brought it closer to this figure and investors eagerly anticipate further gains over time.

About Marathon

Marathon Digital Holdings is a digital asset technology company focused on mining and creating digital assets in the US with an emphasis on blockchain ecosystem. Established in 2010 and headquartered in Fort Lauderdale, Florida since February 2021; previously known as Marathon Patent Group Inc.

Yearly Analysis

Based on current data, Marathon's stock is underperforming relative to its 52-week high but significantly outperforming its 52-week low; this indicates the potential of future gains for the stock. Marathon's expected sales growth projection of 220.8% this year and 41.2% for next year shows strong potential growth potential for the company, and could translate into higher profits and increased stock values. Marathon has reported an EBITDA figure of 142.75 which indicates it is profitable and enjoys healthy cash flow; however, this data alone cannot ascertain its growth potential. Overall, Marathon's stock may present an attractive investment opportunity for those willing to take risks with stocks that have strong growth potential; however, further investigation and analysis must be completed prior to making any investment decisions.

Technical Analysis

Marathon's stock price has recently declined significantly, trading below its 50-day moving average of EUR10.05 and 200-day moving average of EUR10.07. This indicates a downward trend over both short- and long-term periods. Today's trading volume of 39,736,033 represents an increase of 45.58% compared to its average volume of 27,293,300, indicating increased trading activity. Marathon's volatility has fluctuated significantly, falling by negative 1.15% last week, negative 0.61% last month, and positively by 4.38% last quarter. Marathon has recorded its highest average weekly volatility amplitude as 3.63% this week; last month it hit 4.03 and most recently by 4.38 and 4.38 in quarterly terms. Marathon's stock may currently be overbought (>=80), which could indicate it may be time for a correction in the near future. Marathon's stock has recently experienced a downward trend with increased trading activity and volatility, prompting investors to exercise caution when making investment decisions.

Quarter Analysis

According to Marathon's data, its sales growth is impressive: its sales increased by 744.3% during this quarter and are expected to experience another significant jump of 387.9% by next quarter - an encouraging sign for investors. Marathon's growth estimates for both this quarter and next are 83.1 and 92.5 respectively, showing that its expansion should continue. Marathon's year-over-year quarterly revenue growth stands at 228% with current totals totaling 174M for twelve trailing months - which signals that Marathon's revenue has steadily been increasing over time and provides investors with positive signals. Overall, Marathon's impressive sales growth, positive growth estimates and steady revenue expansion is indicative of its strong performance and may represent an excellent investment opportunity in the stock market. Before making any decisions about investments such as Marathon however, it is vital to conduct sufficient research and take all factors into consideration prior to making your final choice.

Equity Analysis

Based on Marathon's financial data, their trailing twelve months EPS stands at EUR-4.05. This indicates that they have experienced a loss per share over the last year; an indication of potential non-profitability, which could pose risks for investors. Return on Equity (ROE) for the twelve trailing months was negative -76.14%, signalling poor profitability. A negative ROE could serve as an early warning sign to investors; such an indication indicates that shareholder equity is being utilized improperly to generate profits and could indicate underutilization by management. Overall, these financial metrics suggest Marathon may not be performing well financially and could be cause for alarm among prospective investors. Therefore, it is wise to carefully consider all relevant data when making investment decisions.

More news about Marathon (MARA).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com